Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

BeOne Medicines' tarlatamab receives China approval for extensive-stage small cell lung cancer following Ph2/3 trials
Antibody, cancer, bispecific antibody, small cell lung cancer, extensive-stage disease - Read more

EMA approves Novo Nordisk's Wegovy (semaglutide) for 48-hour room temperature delivery in obesity treatment
Protein therapy, metabolic, GLP-1 agonist, obesity, semaglutide - Read more

Miltenyi Biomedicine's zorpocabtagene autoleucel achieves remission in three autoimmune diseases in single Ph1/Ph2 patient
Cell therapy, autoimmune, CAR-T, autoimmune hemolytic anemia, CD19 target, B-cell depletion - Read more

GSK advances mocertatug rezetecan (Mo-Rez) targeting B7-H4 to Ph3 trials for ovarian and endometrial cancers
Antibody-drug conjugate, cancer, gynecologic cancer, ovarian cancer, endometrial cancer, B7-H4 target - Read more

Science 2 Sales builds and runs the entire outbound engine (across email, LinkedIn, and cold calling) for companies selling into biotech & pharma - so your sales team stops researching and starts closing qualified meetings with the decision-makers who can actually sign.

When it comes to outbound lead gen - you get the meetings. We handle everything else.

Learn more and book a free strategy call on our website.

Vivatides Therapeutics raises $54M Series A, RNA delivery beyond liver
RNA therapeutics, platform technology, extrahepatic delivery, preclinical - Read more

Seaport Therapeutics files for $100M IPO, neuropsychiatric oral therapies development
Neuropsychiatric, clinical-stage, platform technology, CNS disorders - Read more

Hemab Therapeutics files $100M IPO, antibody therapies for coagulation disorders
Coagulation disorders, antibody, rare disease, clinical-stage - Read more

Biotech VCs increase new investments to 65% in Q1 2026, reversing years of portfolio focus
Venture capital, strategic, financial, investment - Read more [Paywall]

Sun Pharma readies $12B binding offer to acquire women's health company Organon amid competing bids
Women's health, strategic, major transaction, competitive - Read more

HHS updates ACIP charter to emphasize vaccine safety research and adverse effects identification
Vaccine, infectious disease, regulatory, operational - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

FDA rejects Replimune's RP1 (vusolimogene oderparepvec) for advanced cutaneous melanoma for second time
Oncolytic immunotherapy, cancer, oncolytic virus, melanoma, combination therapy - Read more

Novartis cuts 114 jobs at New Jersey headquarters as rare disease sales team restructuring continues
Monoclonal antibody, rare disease, operational, cost reduction - Read more

USP report warns 100 essential drugs face shortage risks from key starting material sourcing bottlenecks
Multiple modalities, multiple therapeutic areas, operational, supply chain risk - Read more

FDA accuses Amneal and BioCorRx of producing false and misleading drug promotional materials
Biosimilar, oncology, small molecule, opioid addiction, regulatory, operational - Read more

FDA launches new mifepristone safety study after Louisiana court preserves mail dispensing access
Small molecule, reproductive health, regulatory, operational - Read more

EMA panel flags liver injury risk for Angelini seizure drug Ontozry after severe hepatic failure reports
Small molecule, neurological, regulatory, operational - Read more

GSK withdraws Wellcovorin (leucovorin) application previously approved for cerebral folate deficiency with autistic features
Small molecule, neurological, folate metabolism, autism spectrum disorder, cerebral folate deficiency - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here